Nohla’s universal donor product candidate, dilanubicel (NLA101), has been used to treat over 100 patients to date with the goal of providing meaningful therapeutics to those who have limited options. These patients are the reason we are here. For more information on our products or our ongoing clinical trials, we invite you to visit the Our Products section of our web site.
The Reason We’re Here
The father of two noticed bumps under his chin, and after visiting several doctors he was told that he needed to act quickly starting treatment. A bone marrow transplant was presented as the best treatment option, but a matching donor could not be found among his family or in the donor registry. With the aid of his referring physician Gregg discovered the cord blood transplantation research being conducted by Dr. Delaney at Fred Hutchinson Cancer Research Center. Gregg received a double cord blood transplant with the addition of off the shelf expanded cord blood cells (dilanubicel/NLA101) in Dr. Delaney’s clinical trial. He and his family remain grateful to the researchers who made the expanded cord blood transplant possible.
When Crystal’s cancer returned, she thought she was out of options. Crystal had already received chemotherapy to treat the acute myeloid leukemia first diagnosed in 2011, when she was 25. Years later, she was told she needed a stem-cell transplant. However, Crystal couldn’t find a match, or someone to donate bone marrow or blood stem cells. “There was no match in the whole world — not even a bad match,” Crystal recalled. Here is Crystal’s story of recovery after receiving a cord blood transplant.